"Her-vaxx was tested initially in a patient population similar...

"Her-vaxx was tested initially in a patient population similar to the one where Herceptin was approved"

Oh, really? Screenshot from HER-vaxx OS ann from 23/11/2020. Looks like Herceptin wasn't being used in those populations. In fact, targetting populations that Herceptin was not being used in was IMUs entire plan for HER-vaxx.



"The Check-Vacc dosages you are quoting are also very small. We will find out this coming week whether CF33 at higher dosages is going to build on already solid results. Mind you RP2D hasn't been reached yet. So if IMU have done another data cut and results are looking better than before, happy days."

Well, this is good because I think it's difficult to look much worse. What do PV701, Reolysin, GM-CSF, ICOVIR-7, and HSP70 have in common? They are OVs that showcase similar objective responses to CF33 in the same patient populations and have all failed to reach approval. Reolysin was granted fast track approval for metastatic breast cancer and orphan drug designation for pancreatic and ovarian cancer, but has failed to showcase anything meaningful clinically.






"How can you also say cancer therapies need to be cytotoxic agents? Having seen a few people go through chemo, I'd say patients would be much better off if there were an alternative to strong cytotoxic agents like chemo. Also, keep in mind the best-selling cancer therapies aren't cytotoxic agents, they are agents that cause the death (cytotoxicity) of cancer cells 'indirectly' by an immune response."

Because in order to be able to achieve a meaningful response, you have to kill cancer cells. Cytotoxicity is cell death - doesn't matter which way you spin it. It could be DNA damage, microtubule disruption, cell signalling interference, apoptosis or autophagy, immune activation, protein degradation, or many other things. The best selling drugs in the world are so because they actually work. Also, it depends how you classify best-selling - if you mean doses prescribed each year, then the best drug is actually doxorubicin which is an anthracycline and one of the most toxic agents there is. All of the drugs listed below are cytotoxic agents.



Cholangiocarcinoma market ≠ gastric cancer market

"Also, regarding your comment about IT applications in the real world, it is low. Again, I feel you have a preference for general cytotoxic agents here, which kill fast-replicating cells wherever they are found, rather than a highly target therapy or one that benefits from replication like an OV. See here and here for a papers that discusses this. Also many cancers cant be cut out and aren't responders. Even skin cancer that has become large and growing rapidly cant be surgically removed. Or tumours close or growing near on vital organs/arteries, so yea IT is highly relevant IF you are talking about immunotherapies."

I think you misunderstand the area you are talking about. General cytotoxic agents that I am talking about have performed better than intratumoral OV administrations since the invention of the word. These chemotherapies include broad acting agents like anthracyclines as well as precision and targetted therapies such as monoclonal antibodies, anti-PD1/PDL1 therapies, TKI inhibitors, and the like. My preference is highly specific targetting of certain cancer characteristics where sensitivity to tumorigenesis is shown, overcoming stem cell adaptation, and eliminating the disease for good. If you look below, there are two great examples of how the inclusion criteria changes for a precision oncology drug and a general cytotoxic agent - I've highlighted the key points. The first screenshot is of Keytruda which select patients based on the companion diagnostic (targetted therapy) and the second is CF33 which selects any patient (general). Of course, this has to do with the nature and stage of the research your company is doing, but the fact remains that just because you manually inject it into a cancer does not make it targetted.